trending Market Intelligence /marketintelligence/en/news-insights/trending/grYoQxHC-e8-NwfUjI65JA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Update: Alexion to acquire Achillion for $930M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Update: Alexion to acquire Achillion for $930M

Boston-based biotechnology company Alexion Pharmaceuticals Inc. said it was acquiring Achillion Pharmaceuticals Inc. for an initial payment of $930 million.

The company agreed to pay $6.30 for every Achillion share it acquires and will make further payments if Achillion meets certain clinical and regulatory milestones.

These milestones include $1 per share if the Achillion's blood disorder drug danicopan, or ACH-4471, is approved in the U.S. where it has the Food and Drug Administration's breakthrough-therapy tag to treat paroxysmal nocturnal hemoglobinuria, or PNH, as well as orphan-drug designation to treat C3 glomerulopathy and PNH, both rare diseases.

Achillion investors will also receive $1 per share if the company initiates a phase 3 trial of its oral factor D inhibitor ACH-5228.

Danicopan, or ACH-4471, is in phase 2 development, while ACH-5228 is in phase 1.

SNL Image

As part of the agreement, Alexion will also acquire the cash assets of Achillion, which stood at about $230 million as of Sept. 30. The actual amount will only be verifiable once the transaction closes, Alexion said in an Oct. 16 press release.

The companies expect to close the transaction in the first half of 2020 after getting approval from Achillion's shareholders and satisfying customary closing conditions.

Blue Bell, Pa.-based Achillion reduced its workforce by about 20% in 2018 as part of its operational restructuring plan to cut expenses and focus on developing its existing clinical and late-stage preclinical factor D inhibitors.